Atrophic Gastritis Predicts the Risk of Gastric Cancer

Shanghai Jiao Tong University School of Medicine

Status: Enrolling

Conditions: Atrophic Gastritis

Treatments: Other: Esophagogastroscopy (OLGA II); Other: Esophagogastroscopy (OLGA III-IV); Other: Esophagogastroscopy (OLGA 0-Ⅰ)

Study type: Observational

Funder types: Other

Identifiers

NCT06203327

rjhy20230004

Details and patient eligibility

About

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Enrollment: 2,042 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ability and willingness to participate in the study and to sign and give informed consent
• Biopsies were collected based on the recommendation of updated Sydney system

Exclusion criteria

• under 18 or over 80 years old
• history of gastrectomy
• severe systemic diseases or malignancy

Trial design

2,042 participants in 3 patient groups

OLGA 0-I

Treatment:

Other: Esophagogastroscopy (OLGA 0-Ⅰ)

OLGA II

Treatment:

Other: Esophagogastroscopy (OLGA II)

OLGA III-IV

Treatment:

Other: Esophagogastroscopy (OLGA III-IV)